Greenbrook Health

Greenbrook Health Centers (GBNH) Changing the Way Depression is Treated.

Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of Excellence https://youtu.be/yrr-wlFftT0

Hapbee (HAPB) Expands Leadership Team to Support Aggressive Growth Strategy

VANCOUVER, BC, Aug. 6, 2021 /CNW/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company"), the leading wearable, wellness technology company has...
Biotech Stock Review, DYAI

Dyadic (DYAI) Scores $10M deal with Sorrento Therapeutics (SNRE).

Share Price up 27% ($4.63 up $1.04) as Wall Street Sorts out the Terms of the Deal. We've had...

Resuming Coverage on PetVivo (PETV).

After Being up 1,035%, Raising $11 Million, Upgrading to NASDAQ, and Retreating 87% From its High, we Resume Coverage.
Biotech Stock Review

Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
ehave,

Telehealth: Contactless Health Screening from Ehave (EHVVF) and VastMinz.

Contactless Health Screening Ehave acquires License covering G-20 Countries for all Psychedelic use, AI-Powered Telehealth Technology To Capture Physiological...

Huge News at Ehave Inc.(EHVVF), our Favorite Psychedelic.

We just finished compiling the 2021 Psychedelic Investor Guide and reviewed 44 companies - in all shapes and sizes. Excluding Johnson &...

Up 2,950% is Novavax (NVAX) Still a Buy?

Up 4,002% at it's peak from where we added it to the Corona Stock Review Watch List at 7.80, Thomas Niel from...

Aditxt, (ADTX) Inc. Working on Antiviral Oral Therapy for COVID-19.

Target Acquisition Has Operational and Sales Footprint in Europe, Asia, and the Middle East LIVE QUOTE
Ehave, Psychedelic Stock Review

Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company

WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE What exactly is a favorite? First...

Latest article

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Added Citius to the Watch List, and it Looks Better Than Ever!

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...

GeoVax (GOVX) Launches Vaccine Manufacturing System.

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...